Evidence map›Paper›PMID 39598749›Full record

ArticleMolecules (Basel, Switzerland)2024

N-Aryl Benzimidazole and Benzotriazole Derivatives and Their Hybrids as Cytotoxic Agents: Design, Synthesis and Structure-Activity Relationship Studies.

Yulia R Aleksandrova, Natalia S Nikolaeva, Inna A Shagina, Karina D Smirnova, Alla A Zubishina, Alexander I Khlopotinin, Artem N Fakhrutdinov, Alexander L Khokhlov, Roman S Begunov, Margarita E Neganova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yulia R AleksandrovaNesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Moscow 119991, Russia.ORCID 0000-0002-5370-3370
Natalia S NikolaevaInstitute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka 142432, Russia.
Inna A ShaginaNesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Moscow 119991, Russia.
Karina D SmirnovaFaculty of Biology and Ecology, P. G. Demidov Yaroslavl State University, Yaroslavl 150003, Russia.
Alla A ZubishinaFaculty of Biology and Ecology, P. G. Demidov Yaroslavl State University, Yaroslavl 150003, Russia.ORCID 0009-0004-5314-8006
Alexander I KhlopotininFaculty of Biology and Ecology, P. G. Demidov Yaroslavl State University, Yaroslavl 150003, Russia.ORCID 0000-0003-4179-7418
Artem N FakhrutdinovN. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow 119991, Russia.ORCID 0009-0001-0502-5974
Alexander L KhokhlovInstitute of Pharmacy, Yaroslavl State Medical University of the Ministry of Health of the Russian Federation, Yaroslavl 150000, Russia.
Roman S BegunovFaculty of Biology and Ecology, P. G. Demidov Yaroslavl State University, Yaroslavl 150003, Russia.ORCID 0000-0002-4610-9744
Margarita E NeganovaNesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Moscow 119991, Russia.ORCID 0000-0001-9346-5920

Funding

the Ministry of Science and Higher Education of the Russian Federation (INEOS RAS) 075-00277-24-00the Ministry of Science and Higher Education of the Russian Federation (IPAC RAS) FFSG-2024-0021
6 · The paper itself

Abstract

The era of chemotherapy began in the 1940s, which is the basis of traditional antitumor approaches and, being one of the most high-tech treatment methods, is still widely used to treat various types of cancer. A promising direction in modern medicinal chemistry is currently the creation of hybrid molecules containing several pharmacophore fragments of different structures. This strategy is successfully used to increase the therapeutic efficacy of cytotoxic agents and reduce side effects. In this work, we synthesized 10 1-aryl derivatives of benzimidazole and benzotriazole and 11 hybrids based on them. Among the compounds obtained, the most promising hybrid molecules were diphenylamines, containing an amino group and a benzotriazole cycle in the

Indexed as

Antineoplastic AgentsBenzimidazolesDrug DesignTriazolesAntioxidantsCell Line, TumorCell MovementCell ProliferationDrug Screening Assays, AntitumorHumansMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsAntioxidantsbenzimidazoleBenzimidazolesbenzotriazoleTriazolesanticancer agentsantioxidantsbenzimidazolesbenzotriazolescell migrationcytotoxicitydiphenylaminesheterocycleshybrid molecules

Identifiers

PMID39598749
PMCPMC11596563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.